Oncothyreon reports full year and fourth quarter 2007 financial results

    BELLEVUE, WA, March 10 /CNW/ - Oncothyreon Inc. (Nasdaq:   ONTY) (TSX: ONY)
(the "Company") today reported financial results for the year and quarter
ended December 31, 2007. All results are in U.S. dollars and prepared using
    Net loss for the year ended December 31, 2007, was $20.3 million or $1.04
per basic and diluted share, compared with $36.4 million, or $2.38 per basic
and diluted share in 2006. The substantial decrease in net loss when compared
with 2006 primarily reflects the charge of $24.9 million in 2006 related to
the acquisition of ProlX Pharmaceuticals, Inc. General and administrative
expenses increased by $4.2 million for the year ended December 31, 2007,
compared with the year ended December 31, 2006, primarily due to costs
associated with the Company's reincorporation into the United States and
certain costs associated with a reduction in administrative staff. Revenue
from operations for the year ended December 31, 2007, was $3.8 million,
compared to $4.0 million in the prior year.
    Net loss for the quarter ended December 31, 2007, was $5.2 million or
$0.26 per basic and diluted share, compared with $27.1 million or $1.58 per
basic and diluted share for the comparable period in 2006. Revenue from
operations was $1.9 million, compared to $1.1 million for the same period in
2006. Expenses for the quarter were $7.1 million, compared with $28.7 million
for the comparable period in 2006, which included charges of $24.9 million
relating to the October 2006 acquisition of ProlX.
    As of December 31, 2007, Oncothyreon's cash, cash equivalents and
short-term investments were $24.2 million, compared to $28.4 million at the
end of 2006, a decrease of $4.2 million, or 14.8 percent. The net decrease
reflects operating expenditures of $22.8 million in 2007 offset by $15.8
million in cash received under the Company's collaborative and contract
manufacturing agreements. The decrease was also offset by the favorable effect
of exchange rate fluctuations on cash and cash equivalents of $1.7 million and
short-term investments of $1.9 million.

    Financial Guidance

    Oncothyreon believes the following financial guidance to be correct as of
the date provided. The Company is providing this guidance as a convenience to
investors and assumes no obligation to update it.

    For 2008, Oncothyreon expects expenses to increase over 2007 as a result
of increased manufacturing and process development activities for Stimuvax(R)
and more advanced clinical development activity for the Company's small
molecule drugs. The Company expects these expenses to be partially offset by
increased revenue related to the purchase of Stimuvax clinical supplies by
Merck KGaA. As a result, Oncothyreon anticipates that operating cash
requirements for 2008 will be between $17 million and $19 million. The Company
estimates that it currently has sufficient cash resources to last into the
second quarter of 2009.

    Business Update

    Key achievements for Oncothyreon in 2007 included:
    -   Initiating a Phase 2 trial of PX-12 in patients with advanced
        pancreatic cancer.
    -   Initiating the START trial, a Phase 3 trial of Stimuvax in patients
        with Stage III non-small cell lung cancer, in partnership with
        Merck KGaA.
    -   Successfully manufacturing Stimuvax vaccine and placebo for the START
    -   Filing an IND and initiating a Phase 1 trial of PX-478 in patients
        with advanced solid tumors or lymphomas.
    -   Signing amended and restated collaboration and supply agreements with
        Merck KGaA for Stimuvax, providing for new, near-term milestones, the
        first of which was received in December 2007.
    -   Completing the reincorporation of Biomira into the United States as

    Conference Call and Webcast

    Oncothyreon's management will discuss the Company's fourth quarter and
full year 2007 financial results as well as general business updates during a
conference call beginning at 1:30 p.m. PT/ 4:30 p.m. ET today, Monday,
March 10, 2008. To listen to a webcast of the discussion, visit

    About Oncothyreon

    Oncothyreon is a biotechnology company specializing in the development of
innovative therapeutic products for the treatment of cancer. Oncothyreon's
goal is to develop and commercialize novel synthetic vaccines and targeted
small molecules that have the potential to improve the lives and outcomes of
cancer patients. For more information, visit www.oncothyreon.com.

    Forward-Looking Statements

    In order to provide our investors with an understanding of our current
results and future prospects, this release may contain statements that are
forward-looking. Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects," "will,"
"intends," "potential," "possible" and similar expressions are intended to
identify forward-looking statements. These forward-looking statements include
Oncothyreon's expectations regarding expenses related to manufacturing and
process development activities and clinical development activities, revenues
resulting from Merck's purchase of Stimuvax supplies, and the use and adequacy
of cash resources.
    Forward-looking statements involve risks and uncertainties related to our
business and the general economic environment, many beyond our control. These
risks, uncertainties and other factors could cause our actual results to
differ materially from those projected in forward-looking statements,
including the risks associated with the adequacy of financing and reserves on
hand, currency exchange rate fluctuations, changes in general accounting
policies, our ability to remediate an identified material weakness in our
internal controls, general economic factors, achievement of the results we
anticipate from our clinical trials with our products and our ability to
adequately obtain and protect our intellectual property rights. Although we
believe that the forward-looking statements contained herein are reasonable,
we can give no assurance that our expectations are correct. All
forward-looking statements are expressly qualified in their entirety by this
cautionary statement. For a detailed description of our risks and
uncertainties, you are encouraged to review the official corporate documents
filed with the securities regulators in the United States on U.S. EDGAR and in
Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly
update its forward-looking statements based on events or circumstances after
the date hereof.

    Additional Information

    Additional information relating to Oncothyreon can be found on U.S. EDGAR
at www.sec.gov and on SEDAR at www.sedar.com.

                             Oncothyreon Inc.(1)
                 Consolidated Statements of Operations Data
       (in thousands of U.S. dollars, except share and per share data)

                                 Three Months Ended          Year Ended
                                     December 31             December 31
                               ----------------------  ----------------------
                                   2007        2006        2007        2006
                               ----------  ----------  ----------  ----------
      Contract research and
       development............  $     29   $   1,028   $     631   $   3,678
      Contract manufacturing..     1,617           -       2,536           -
      Licensing revenue from
       agreements.............       212          43         528         182
      Licensing, royalties
       and other revenue......        80          38         103         119
                                ---------  ----------  ----------  ----------
                                   1,938       1,109       3,798       3,979
                                ---------  ----------  ----------  ----------

      Research and
       development............     2,278       2,885      10,011      12,200
      Manufacturing...........     1,396           -       2,564           -
      General and
       administrative.........     3,567       2,298      11,797       7,636
      Marketing and business
       development............        26         134         565         587
      Depreciation............        84          56         246         247
      In-process research and
       development............         -      24,920           -      24,920
      Investment and other
       loss (income)..........       (22)       (373)        371        (916)
      Interest expense........         3           2           5          10
      Change in fair value of
       warrant liability......      (242)     (1,238)     (1,421)     (3,849)
                                ---------  ----------  ----------  ----------
                                  (7,090)    (28,684)    (24,138)    (40,835)
                                ---------  ----------  ----------  ----------
    Loss before income taxes..    (5,152)    (27,575)    (20,340)    (36,856)
    Income tax recovery
      Current.................         -         462           -         462
                                ---------  ----------  ----------  ----------
    Net loss..................  $ (5,152)  $ (27,113)  $ (20,340)  $ (36,394)
                                ---------  ----------  ----------  ----------
                                ---------  ----------  ----------  ----------
    Basic and diluted loss
     per share................  $  (0.26)  $   (1.58)  $   (1.04)  $   (2.38)
                                ---------  ----------  ----------  ----------
                                ---------  ----------  ----------  ----------
    Weighted average number of
     common shares outstanding
     (in thousands)...........    19,486      17,133      19,486      15,317
                                ---------  ----------  ----------  ----------
                                ---------  ----------  ----------  ----------

                             Oncothyreon Inc.(1)
                       Consolidated Balance Sheets Data
              (in thousands of U.S. dollars, except share data)

                                                   December 31,  December 31,
                                                          2007          2006
    Cash, cash equivalents and short term
     investments.................................. $    24,186   $    28,395
    Total assets.................................. $    36,218   $    33,456
    Total long-term liabilities................... $    12,526   $     2,328
    Shareholders' equity.......................... $    12,019   $    27,435
    Common shares outstanding.....................  19,485,889    19,485,889

    (1) On December 10, 2007, Oncothyreon became the successor corporation to
        Biomira Inc. by way of a plan of arrangement effected pursuant to
        Canadian law. These financial statements reflect the historical
        accounts of Biomira up to December 10, 2007, with the exception of
        basic and diluted loss per share and common shares outstanding, which
        have been recast to reflect the 6 for 1 common share exchange
        effected by the plan of arrangement.

For further information:

For further information: Investor and Media Relations Contact: Julie
Rathbun, Rathbun Communications, (206) 769-9219, ir@oncothyreon.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890